Immage Biotherapeutics

Immage Biotherapeutics is built on the foundational understanding that many cancers can be treated by harnessing the power of the human immune system. The company’s pipeline includes a DNA viral vaccine construct targeting tumors expressing Melanoma Antigen Family-A (MAGE-A) antigens. The company has a therapeutic pipeline with a high probability of success, as our treatments aim to address unmet medical needs in patient populations. Our leading pipeline candidate is a universal vaccine applicable to any tumor expressing the MAGE-A tumor antigen. This treatment can target cancers with high expression of MAGE-A antigens, including breast, colon, pancreatic, glioblastoma, and esophageal squamous cell carcinoma, for example. The company anticipates focusing on developing therapeutics for triple-negative breast cancer.